Company Filing History:
1 out of 123 
1 out of 262 Years Active: 2024
Title: Innovations of Nicholas Paul Richards in Isoindolinone Derivatives
Introduction
Nicholas Paul Richards is an accomplished inventor based in Haverhill, GB, known for his significant contributions to medicinal chemistry. He holds a patent that focuses on isoindolinone inhibitors, showcasing his expertise in developing novel therapeutic compounds aimed at enhancing drug efficacy.
Latest Patents
Richards' notable patent is titled "Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them." This invention pertains to innovative processes for preparing isoindolin-1-one derivatives, particularly the (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. Furthermore, the invention also covers various crystalline forms and salts of this compound, reflecting its potential utility in addressing medical challenges.
Career Highlights
Throughout his career, Nicholas Paul Richards has collaborated with leading organizations in the pharmaceutical industry. He has worked with Astex Therapeutics Limited and Cancer Research Technology Limited, contributing to research and development efforts focused on advancing cancer therapies.
Collaborations
In his innovative journey, Richards has worked alongside notable colleagues such as Steven Howard and Benjamin David Cons. Their collaborative efforts have significantly influenced the progress of projects aimed at exploring novel therapeutic pathways and addressing pressing health issues.
Conclusion
In conclusion, Nicholas Paul Richards exemplifies the spirit of innovation within the field of medicinal chemistry. His patent on isoindolinone inhibitors not only underscores his expertise as an inventor but also highlights the potential benefits his work may bring to therapeutic approaches in cancer treatment. As he continues to advance research initiatives, the contributions of Richards and his collaborators will undoubtedly leave a lasting impact on the healthcare landscape.